ClinicalTrials.gg
Enrolling by invitationNCT05608603Updated Mar 20, 2024

Diagnostics of Coronavirus Disease 2019 Cardiovascular Complications

An observational study in COVID-19, Endothelial Function and Diastolic Dysfunction, sponsored by I.M. Sechenov First Moscow State Medical University. Enrolling by invitation at 1 site in Russian Federation. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by I.M. Sechenov First Moscow State Medical University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in COVID-19 by I.M. Sechenov First Moscow State Medical University — 1 open to participants now, 1 under way, none of them phase 3. COVID-19 · I.M. Sechenov First Moscow State Medical University.

Started
2022
the only one that year
Observational
5 of 10
1 open now
Registered
9th of 10
by date

Among the 10 studies in COVID-19 by I.M. Sechenov First Moscow State Medical University, this one is the only one that started in 2022, is one of 5 observational ones, and was the 9th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 10 studies in COVID-19 by I.M. Sechenov First Moscow State Medical University is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in COVID-19 by I.M. Sechenov First Moscow State Medical University, or all of them as a file.
02

Study summary

Aim of this prospective, observational, multi-centered, randomized study is to detect cardiovascular complications in patients after coronavirus infection.

The study will include 100 patients who underwent confirmed by laboratory tests COVID-19 infection (polymerase chain reaction (PCR) testing, enzyme-linked immunosorbent assay (positive result at least 1 time)) 1-3 months ago with the degree of lung lesion more than 25%, who were admitted to the University Clinical Hospital No. 4 of I.M. Sechenov First Moscow State Medical University.

The study consists of 4 periods:

  1. Screening for up to 6 months.
  2. Inclusion in the study, undergoing of identical laboratory and instrumental testing.
  3. Re-examination of patients. After 6 months from the initial examination (9 months after discharge from the infectious diseases department), patients will be re-examined.

4 Determination of end points, statistical data processing.

Estimated result of the study is to confirm or refute the hypothesis:

  1. As a result of the analysis of ECG and pulse wave data and comparison with echocardiography data, identify cardiovascular complications of COVID-19 infection.
  2. To determine the diagnostic significance of pulse wave parameters for assessing cardiovascular complications in patients with a history of COVID-19 infection (sensitivity, specificity, positive and negative predictive value).
  3. Identify correlations between pulse wave parameters and biochemical markers of endothelial dysfunction (endothelin-1).
  4. As a result of the analysis of exhaled air by the proton mass spectrometry, to identify markers of cardiovascular complications in patients after COVID-19 infection.
  5. As a result of a cardiorespiratory stress test, determine the respiratory and cardiovascular causes of dyspnea, exercise tolerance of patients after infection with COVID-19.
Read the detailed description

Aim of this prospective, observational, multi-centered, randomized study is to detect cardiovascular complications in patients after coronavirus infection.

The study will include 100 patients who underwent confirmed by laboratory tests Coronavirus Disease 2019 (COVID-19) infection (polymerase chain reaction (PCR) testing, enzyme-linked immunosorbent assay (positive result at least 1 time)) 1-3 months ago with the degree of lung lesion more than 25%, who were admitted to the University Clinical Hospital No. 4 of I.M. Sechenov First Moscow State Medical University.

The study consists of 4 periods:

  1. Screening for up to 6 months. Performed by a pulmonologist. Patients meeting the inclusion criteria are selected.
  2. Inclusion in the study. If the patient meets the inclusion criteria, a discussion about the nature of the study is held with the patient. Further, consent to participate in the study and to process personal data is obtained. After, the epicrisis from the COVID-19 infectious diseases department is analyzed.

    Patients are provided with medical care in accordance with the standards approved by the Ministry of Health of the Russian Federation, and local acts of the institution in which the study is carried out.

    Patients eligible for inclusion will undergo the following investigations:

    • Anamnesis and complaints collection; physical examination;
    • Assessment of the quality of life and psycho-emotional status using the Short Form-36 (SF36) and Hospital Anxiety and Depression Scale (HADS) questionnaires, as well as the six-minute walk test;
    • General and biochemical blood tests , urine analysis, , determination of biochemical markers of endothelial dysfunction (endothelin-1) in the blood;
    • Electrocardiography, a flow mediated dilatation procedure for endothelial function assessment, transthoracic echocardiography to identify the structural and functional features of the myocardium, spiroergometry to determine the patient's oxygen consumption.
    • Electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor "CardioQvark"
    • The analysis of exhaled air will be performed using the Compact proton mass spectrometer (PTR-MS) manufactured by Ionicon (Austria).
  3. Re-examination of patients. After 6 months from the initial examination (9 months after discharge from the infectious diseases department), patients will be re-examined, In the interval between the initial and repeated examinations, the condition of all patients will be monitored, for this it is expected to make phone calls, the frequency of 1 time per month.

4 Determination of end points, statistical data processing. The statistical processing will be performed using the Python Software Foundation version 3.8 for Windows (Delaware, USA).

Estimated result of the study is to confirm or refute the hypothesis:

  1. As a result of the analysis of ECG and pulse wave data and comparison with echocardiography data, identify cardiovascular complications of COVID-19 infection.
  2. To determine the diagnostic significance of pulse wave parameters for assessing cardiovascular complications in patients with a history of COVID-19 infection (sensitivity, specificity, positive and negative predictive value).
  3. Identify correlations between pulse wave parameters and biochemical markers of endothelial dysfunction (endothelin-1).
  4. As a result of the analysis of exhaled air by the proton mass spectrometry, to identify markers of cardiovascular complications in patients after COVID-19 infection.
  5. As a result of a cardiorespiratory stress test, determine the respiratory and cardiovascular causes of dyspnea, exercise tolerance of patients after infection with COVID-19.
03

Conditions studied

  • COVID-19
  • Endothelial Function
  • Diastolic Dysfunction
  • Oxygen Consumption
  • Quality of Life
  • Exercise Tolerance

Browse trials for

Keywords

  • COVID-19
  • markers of endothelial function
  • diastolic dysfunction
  • oxygen consumption
  • flow mediated dilatation
  • proton mass spectrometry
  • remote ECG monitoring
  • pulse vawe
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

The study population consist all men and women from 18 to 80 age in a community according inclusion, non-inclusion, exclusion criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written to participate in the study;
  2. Age 18 and over;
  3. Male and female;
  4. COVID-19 infection confirmed by laboratory tests (polymerase chain reaction testing, enzyme-linked immunosorbent assay (positive result at least 1 time) with a CT degree more that 25% of lung lesion.
  5. No more than 3 months after discharge from infectious department

Non-inclusion criteria:

  1. Unable to sign informed consent;
  2. Mental illness (severe dementia, schizophrenia, severe depression, manic-depressive psychosis);
  3. Acute coronary syndrome, acute cerebrovascular accident, pulmonary embolism within the last 3 months;
  4. Oncology;
  5. Diseases and conditions that can change the picture and complicate the analysis of the ECG (conduction disturbance, pacemaker);
  6. Inability to use a heart monitor (congenital developmental anomalies, traumatic amputation of the upper limbs, essential tremor, Parkinson's disease);
  7. Severe comorbidities with less than 1 year.

Exclusion criteria

Exclusion Criteria:

  1. Refusal to further participation in the study;
  2. Acute infectious diseases, tuberculosis
  3. Oncology arising in the process of the study
  4. Acute coronary syndrome, acute cerebrovascular accident, pulmonary embolism arising in the process of the study
  5. Acute psychotic reactions arising in the process of the study;
  6. Inability to use a heart monitor arising in the process of the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
9 Months
Patient registry
Yes

Groups and cohorts

  • 3 months postcovid patients

    Included 100 patients, aged 18-80 years old, at 3 months after infection COVID-19. Intervention: cardiorespiratory stress test to determine the patient's oxygen consumption; electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor "CardioQvark"; the analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria).

    Diagnostic Test: Portable cardiac monitor "CardioQvark" · Diagnostic Test: Cardiorespiratory stress test · Diagnostic Test: Analysis of exhaled air using the Compact PTR-MS proton mass spectrometer

  • 9 months postcovid patients

    Included the same 100 patients, aged 18-80 years old, at 9 months after infection COVID-19. Intervention: cardiorespiratory stress test to determine the patient's oxygen consumption; electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor "CardioQvark"; the analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria).

    Diagnostic Test: Portable cardiac monitor "CardioQvark" · Diagnostic Test: Cardiorespiratory stress test · Diagnostic Test: Analysis of exhaled air using the Compact PTR-MS proton mass spectrometer

Interventions

  • Diagnostic testPortable cardiac monitor "CardioQvark"

    Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor "CardioQvark" (Russia, LLC "L Card" , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form.

    Also known as: Electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor "CardioQvark"

  • Diagnostic testCardiorespiratory stress test

    Cardiorespiratory stress testing with gas analysis using the Quark CPET diagnostic system (COSMED, Italy). The study protocol will consist of 4 phases: rest, warm-up, exercise and recovery. During the load phase, a ramp protocol will be used with a stepped load from 10 to 25 W/min. The increase in power will be calculated individually before the start of the study so that the test lasts 8-12 minutes until complete muscle failure.

  • Diagnostic testAnalysis of exhaled air using the Compact PTR-MS proton mass spectrometer

    The analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)

06

What researchers measure

Primary outcomes

  1. Changes in endothelin-1 in dynamics (compared with initial indicators)

    This outcome will be assessed by taking blood samples from a peripheral vein

    Time frame: In 9 months after the recovery from COVID-19

  2. Changes in the diastolic function of the right and left ventricles (compared with initial indicators)

    Transthoracic echocardiography (EchoCG) will be performed to assess the heart structure and function: unidimensional (M-mode), two-dimensional (B-mode) and Doppler. Diastolic function of the left ventricle will be assessed using pulse-wave, constant-wave, and tissue Doppler studies. Maximum velocity of early (E peak) and late (A peak) diastolic filling, E/A ratio, time of blood flow deceleration of early left ventricular diastolic filling (DT) will be determined at simultaneous recording of aortic and transmitral blood flow in constant-wave mode, left ventricular isovolumic relaxation time (IVRT) - interval from the end of aortic to the beginning of transmitral blood flow.

    Time frame: In 9 months after the recovery from COVID-19

  3. Change in ejection fraction (compared with initial indicators)

    Transthoracic EchoCG will be performed to assess the heart structure and function: unidimensional (M-mode), two-dimensional (B-mode) and Doppler. Ejection fraction will be assessed according to BIPLANE, TAPSE.

    Time frame: In 9 months after the recovery from COVID-19

  4. Changes in the volumes of the heart cavities (compared with initial indicators)

    Transthoracic EchoCG will be performed to assess the heart structure and function: unidimensional (M-mode), two-dimensional (B-mode) and Doppler.

    Time frame: In 9 months after the recovery from COVID-19

  5. Change in speed indicators on the heart valves (compared with initial indicators)

    Transthoracic EchoCG will be performed to assess the heart structure and function: unidimensional (M-mode), two-dimensional (B-mode) and Doppler.

    Time frame: In 9 months after the recovery from COVID-19

  6. Change in mean and diastolic pressure of the pulmonary artery (compared with initial indicators)

    Transthoracic EchoCG will be performed to assess the heart structure and function: unidimensional (M-mode), two-dimensional (B-mode) and Doppler.

    Time frame: In 9 months after the recovery from COVID-19

  7. Changes in the cardio-ankle vascular index and ankle-brachial index (compared with initial indicators)

    Will be assessed by using pulse wave measurements in dynamics

    Time frame: In 9 months after the recovery from COVID-19

  8. Changes in the spectrum of volatile organic compounds in exhaled air in patients after COVID-19 infection over time (compared with initial indicators)

    Will be assessed by using exhale air proton mass spectrometry in dynamics.

    Time frame: In 9 months after the recovery from COVID-19

  9. Change in oxygen pulse (VO2/HR) at the peak of the load

    The spiroergometric test will be performed under continuous stepwise increasing load. The duration of each load step is 5 min; the initial load level is 25 W, followed by an increase in load at each step by the same amount. The results of the test will be used to evaluate the achievement of the maximum level of oxygen consumption (in l/min or ml/min/kg body weight) and the maximum achievement of the "oxygen pulse" on load.

    Time frame: In 9 months after the recovery from COVID-19

  10. Changes in ventilation parameters (tidal volume (Vt), minute ventilation (VE), Vt/FVC index (ratio of tidal volume to forced vital capacity), respiratory reserve (BR)) over time

    The spiroergometric test will be performed under continuous stepwise increasing load. The duration of each load step is 5 min; the initial load level is 25 W, followed by an increase in load at each step by the same amount. The results of the test will be used to evaluate the achievement of the maximum level of oxygen consumption (in l/min or ml/min/kg body weight) and the maximum achievement of the "oxygen pulse" on load.

    Time frame: In 9 months after the recovery from COVID-19

  11. Changes in gas exchange parameters (end-expiratory partial pressure of exhaled carbon dioxide (PetCO2), ventilation equivalent for carbon dioxide (VE/VCO2), ventilation-perfusion ratio (Vd/Vt)) in dynamics

    The spiroergometric test will be performed under continuous stepwise increasing load. The duration of each load step is 5 min; the initial load level is 25 W, followed by an increase in load at each step by the same amount. The results of the test will be used to evaluate the achievement of the maximum level of oxygen consumption (in l/min or ml/min/kg body weight) and the maximum achievement of the "oxygen pulse" on load.

    Time frame: In 9 months after the recovery from COVID-19

07

Study locations

1 site
  • I.M. Sechenov First Moscow State Medical University (Sechenov University)ogy, Center "Digital biodesign and personalized healthcare")
    Moscow, 119991, Russian Federation
08

References and documents

Individual participant data

Plan to share: No — Prohibition of local ethics committee

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2024, 30 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 30 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2022
First posted
Nov 8, 2022
StartActual
Jun 2, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Nov 30, 2025
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05608603
Responsible party
Sponsor
First posted
Nov 8, 2022
Start date
Jun 2, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Mar 20, 2024

Study contacts

Philippe Yu Kopylov, Professor
study director · I.M. Sechenov First Moscow State Medical University (Sechenov University)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion